BiotechTube

Gardasil vaccine

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Inflammatory Bowel Disease

Conditions

Inflammatory Bowel Disease

Trial Timeline

Jul 1, 2008 → Apr 1, 2011

NCT ID
NCT00727636

About Gardasil vaccine

Gardasil vaccine is a pre-clinical stage product being developed by Merck for Inflammatory Bowel Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00727636. Target conditions include Inflammatory Bowel Disease.

Hype Score Breakdown

Clinical
5
Activity
2
Company
10
Novelty
2
Community
1

Clinical Trials (3)

NCT IDPhaseStatus
NCT01446718Pre-clinicalCompleted
NCT01489527Pre-clinicalCompleted
NCT00727636Pre-clinicalCompleted

Competing Products

20 competing products in Inflammatory Bowel Disease

See all competitors
ProductCompanyStageHype Score
Infliximab + Infliximab + InfliximabCelltrionApproved
85
CT-P13CelltrionPhase 3
77
Subcutaneous infliximab CT-P13 Remsima®SCCelltrionPre-clinical
23
Infliximab subcutaneous + Immunosuppressive AgentsCelltrionPhase 3
77
fidaxomicinAstellas PharmaApproved
85
Eribulin + Adriamycin + CyclophosphamideEisaiPhase 2
52
E6007 + E6007 + E6007 + E6007 + E6007 + E6007EisaiPhase 1
33
Placebo + MORF-057Eli LillyPhase 2
52
Baricitinib + BaricitinibEli LillyPhase 2
52
LY3114062 SC + Placebo + LY3114062 IVEli LillyPhase 1
33
MORF-057 + PlaceboEli LillyPhase 2
52
MORF-057Eli LillyPhase 2
52
LY3009104Eli LillyPhase 1
33
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
52
RisankizumabAbbVieApproved
85
GC012F Injection infusionAstraZenecaPhase 1
33
AZD6793 + PlaceboAstraZenecaPhase 1
33
Human Papillomavirus VaccineMerckApproved
85
PembrolizumabMerckPhase 2
52
BezlotoxumabMerckApproved
85

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85